ASCO Releases Guideline for the Management of Small Renal Masses

Share this content:
ASCO published new recommendations for the management of patients with clinically localized small renal masses.
ASCO published new recommendations for the management of patients with clinically localized small renal masses.

The American Society of Clinical Oncology (ASCO) published new recommendations for the management of patients with clinically localized small renal masses (SRMs) in the Journal of Clinical Oncology.1 The recommendations aim to provide guidance for oncologists, urologists, and nephrologists, as well as mid-level providers, nurses, and patients.

The evidence-based guideline was developed by a multidisciplinary expert panel using data from 83 studies, which included 63 primary studies and 20 systematic reviews.

SRM is defined by the guideline as a contrast-enhancing tumor of a diameter of 4 cm or less, which is typically found incidentally. Commonly, SRMs are stage T1a renal cell carcinoma, but they can be lymphoma, sarcoma, metastasis, or benign cortical tumors.

The guideline indicates that all patients with an SRM should be considered for a biopsy, particularly if the results may change management decisions.

The recommended standard treatment is partial nephrectomy for patients who are eligible for surgery. For tumors that are not amenable to partial nephrectomy, a full nephrectomy should be performed. Percutaneous thermal ablation is recommended as another option for patients in whom the tumor can be fully ablated. For patients with substantial comorbidities or limited life expectancy, the guideline recommends active surveillance.

For patients with chronic kidney disease, or who develop chronic kidney disease after SRM treatment, the guideline recommends that a referral to a nephrologist should be considered.

RELATED: Dalantercept and Axitinib in Renal Cell Carcinoma

Additional recommendations highlight the importance of the clinician-patient relationship with strong communication. ASCO recommends that clinicians should ensure that patients are educated and informed about their disease, and provide or recommend sources of information. All test results should be promptly discussed with the patient and caregiver, and the benefits of clinical trials should be explained.

Reference

  1. Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Jan 17. doi: 10.1200/JCO.2016.69.9645 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters